305 related articles for article (PubMed ID: 31042295)
1. Tardive Dyskinesia: New Treatments Available.
Limandri BJ
J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
[TBL] [Abstract][Full Text] [Related]
2. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
5. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
6. Tardive Dyskinesia: Treatment Update.
Arya D; Khan T; Margolius AJ; Fernandez HH
Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
[TBL] [Abstract][Full Text] [Related]
7. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
8. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
9. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
Kim AP; Baker DE; Levien TL
Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
[TBL] [Abstract][Full Text] [Related]
10. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
12. Two New Drugs for Tardive Dyskinesia Hit the Market.
Morrow T
Manag Care; 2018 Jan; 27(1):35-36. PubMed ID: 29369770
[TBL] [Abstract][Full Text] [Related]
13. FDA-Approved Medications to Treat Tardive Dyskinesia.
McEvoy JP
J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851437
[TBL] [Abstract][Full Text] [Related]
14. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
15. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
16. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
17. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
18. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
Müller T
Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine (Ingrezza) for tardive dyskinesia.
Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
[No Abstract] [Full Text] [Related]
20. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
